We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




HPV Infection Identified In Self-Collected Vaginal Swabs

By LabMedica International staff writers
Posted on 19 May 2016
High risk, potentially cancer causing human papillomavirus infections (HPV) are common among women in the developing world, but self-sampling with vaginal swabs may provide materials that screen as accurately as the more labor-intensive approach using cervical samples obtained by clinicians.

Evaluating self-collected samples was a critical milestone as it would enable same-day screening and treatment. More...
Same-day treatment is needed in high-burden; low-income countries such as Papua New Guinea because when patients leave the clinic, it often becomes impossible to find them again, should their results show that they need treatment.

Scientists at The Kirby Institute (Sydney, Australia) conducted the first evaluation of self-collected vaginal specimens compared with clinician-collected cervical specimens for the detection of high-risk human papillomavirus (hrHPV) infection. Women aged 30 to 54 years attending two well woman clinics in Papua New Guinea were invited to participate and provided self-collected vaginal and clinician-collected cervical cytobrush specimens.

Both specimens were tested at point-of-care using the Xpert HPV test (Cepheid, Sunnyvale, CA, USA). Women were given their cervical test result the same day. Those with a positive hrHPV test and a positive examination on visual inspection of the cervix with acetic acid were offered same-day cervical cryotherapy. A total of 1,005 women were enrolled with 124 (12.3%) positive for any hrHPV infection. There was 99.4% overall percentage agreement (OPA) between vaginal and cervical tests for HPV-16, 98.5% OPA for HPV-18/45; 94.4% OPA for other hrHPV infections, and 93.4% OPA for all hrHPV types.

The authors concluded that self-collected vaginal specimens had excellent agreement with clinician-collected cervical specimens for the detection of hrHPV infection using the Xpert HPV test. This approach provides for the first time an opportunity to incorporate point-of-care hrHPV testing into clinical cervical screening algorithms in high-burden, low-income settings.

Andrew Vallely, PhD, an Associate Professor and corresponding author of the study said, “This is the first time there's been a direct comparison between self-collected vaginal swabs and clinician-collected cervical specimens using a screening device that can provide same day results.” The study was published online on April 13, 2016, in the Journal of Clinical Microbiology.

Related Links:
The Kirby Institute
Cepheid

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.